Democratic presidential candidate Hillary Clinton has unveiled a plan aimed at curbing the costs of prescription drugs.
Clinton is set to formally unveil the plan at a campaign event in Iowa on Tuesday afternoon, where she is also expected to detail other proposals to address consumers' out-of-pocket spending on health care.
The plan would place a $250 monthly limit on consumers' out-of-pocket spending for drugs covered by their health plans, which the Clinton campaign estimates would affect up to one million Americans annually.
Clinton's plan would also:
- Allow Medicare to negotiate drug prices;
- Allow U.S. residents to import medications from outside the country;
- End so-called pay-for delay settlements, in which makers of brand-name drugs pay generic drugmakers to ensure the delayed release of generic competitors;
- End a tax credit for direct-to-consumer drug advertising;
- Reduce the monopoly marketing period for biologics from 12 years to seven years;
- Require companies that receive federal funding for basic research to invest a certain amount in research and development; and
- Require larger prescription rebates for low-income Medicare beneficiaries that are equivalent to those currently offered under Medicaid.
The campaign said the plan would save more than $100 billion over a decade, which would come from the proposal's Medicare rebates.
More from the presidential race
Clinton says she would protect ACA from repeal
Meanwhile, Clinton on Monday said that if elected, she would not allow Republican lawmakers to repeal the Affordable Care Act (ACA).
During remarks at a campaign event, Clinton said she would not let Republicans "tear up [the ACA], kick 16 million people off their health coverage and force the country to start the health care debate all over again," adding, "Not on my watch. I want to build on the progress we've made."
Clinton credited the ACA with lowering the U.S. uninsured rate to the lowest it has been in 50 years. She said that keeping the ACA intact is "not just a political issue, it's a moral issue" (Norman, Politico, 9/22; Gearan/Goldstein, "Post Politics," Washington Post, 9/22; Gearan, "Post Politics," Washington Post, 9/21; AP/Modern Healthcare, 9/21; Ferris, The Hill, 9/21).
Next in the Daily Briefing
IOM says patients are dying because of this 'blind spot'—and providers must fix it